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Louis Hospital, Université de Paris, Paris, France, 5 Candiolo Cancer Institute, FPO - IRCCS, Candiolo, Italy
Merkel cell carcinoma (MCC) is a rare and aggressive skin cancer that can metastasize
rapidly. In patients with metastatic MCC (mMCC), brain metastases are uncommon but
are associated with poor prognosis; furthermore, there is limited published literature
regarding treatment of these patients, and no specific regimens are currently
recommended by guidelines. Avelumab, an anti–programmed death ligand 1
monoclonal antibody, was the first approved treatment for patients with mMCC. Here,
we present 4 cases of patients with mMCC and brain metastases treated with avelumab.
Patient age ranged from 48 to 70 years, and all patients received avelumab as second-line
therapy following disease progression with platinum-based chemotherapy. Patient cases
1 and 2 received avelumab alone and experienced rapid disease progression according to
Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). In patient case 3,
avelumab alone resulted in a prolonged complete response by RECIST 1.1 of 1 brain
metastasis and partial response by RECIST 1.1 of a second brain metastasis. After 11
months of avelumab treatment, the patient received concurrent stereotactic radiosurgery
that resulted in complete response of the second metastasis. Patient case 4 achieved a
partial response by RECIST 1.1 with avelumab plus stereotactic radiosurgery. These
results suggest that avelumab followed by radiotherapy or with concurrent radiotherapy
may be an effective treatment option for patients with mMCC and brain metastases.
Keywords: Merkel cell carcinoma, brain metastases, avelumab, immunotherapy, stereotactic radiosurgeryAbbreviations: CK, cytokeratin; CT, computed tomography; ECOG PS, Eastern Cooperative Oncology Group performance
status; MCC, Merkel cell carcinoma; mMCC, metastatic Merkel cell carcinoma; MRI, magnetic resonance imaging; OS, overall
survival; PD, progressive disease; PD1, programmed death 1; PD-L1, programmed death ligand 1; PET, positron emission
tomography; Q2W, every 2 weeks; RECIST 1.1, Response Evaluation Criteria in Solid Tumors version 1.1; SRS,
stereotactic radiosurgery.
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Merkel cell carcinoma (MCC) is a rare neuroendocrine tumor
associated with UV radiation exposure, clonal integration of
the Merkel cell polyomavirus, and immunosuppression (1).
MCC commonly occurs in sun-exposed areas of the body such
as the head and neck region (1). However, in approximately 4-
5% of all patients and 28-40% of those with clinically
detectable nodal disease, the primary lesion cannot be
identified; these cases are associated with a more favorable
prognosis (1–3).
MCC is an aggressive disease that can metastasize early (4); at
diagnosis, approximately 26% and 8% of patients have nodal and
distant metastatic MCC (mMCC), respectively (2). Metastases
usually arise in the lymph nodes, skin, bone, lung, or liver (4).
Brain metastases are less common and occur in approximately 7-
13% of patients with distant mMCC (4–6). In patients with
MCC, the occurrence of brain metastases is associated with a
poor prognosis, with a median overall survival (OS) of
approximately 2 years without neurosurgery (6). There are
limited published data on patients with mMCC and brain
metastases, and many trials in MCC exclude this subset of
patients (6). Furthermore, there are no treatment options
recommended by guidelines specifically for patients with
mMCC and brain metastases (4, 7); however, a possible
survival benefit has been suggested for patients who receive
surgery or radiotherapy (6).
Avelumab, an anti–programmed death ligand 1 (PD-L1)
monoclonal antibody, became the first approved treatment for
mMCC based on promising results in the phase 2 JAVELIN
Merkel 200 trial (8, 9). Patients with brain metastasis were
excluded from this trial. Prior to approval, avelumab showed
clinical benefit in a real-world setting in patients with mMCC
and limited treatment options (including immunocompromised
patients and those with treated brain metastases) in the global
expanded access program (10).
Here, we report the clinical experiences of 4 patients with
mMCC and brain metastases treated with avelumab in Europe.PATIENT CASES
The patient cases are summarized in Table 1.
Patient Case 1
A 70-year-old woman from Italy with hyperuricemia, arterial
hypertension, and hypothyroidism presented with pain and a
growing thigh mass and was diagnosed with mMCC of the left
thigh and multiple nodal metastases (inguinal and paraaortic/
iliac lymph nodes) in October 2016. The patient had a family
history of cancer (gastric cancer and leukemia) and had
previously received a bilateral total knee prosthesis and
undergone a right saphenectomy. Between November 2016 and
March 2017, the patient received 6 cycles of chemotherapy
(cisplatin 25 mg/m2 plus etoposide 100 mg/m2 on days 1-3
every 21 days), with no relevant acute toxicity.Frontiers in Oncology | www.frontiersin.org 2On April 5, 2017, the patient presented with worsened left leg
edema, and a subsequent whole-body positron emission
tomography (PET) scan showed an increase in the number of
metastases of fluorodeoxyglucose uptake compared with the
previous PET scan in November 2016, indicating disease
progression. On April 12, 2017, a whole-body computed
tomography (CT) scan, including the brain, showed
progressive disease (PD) by Response Evaluation Criteria in
Solid Tumors version 1.1 (RECIST 1.1) with increased size of
the left leg edema and left inguinal lymph node metastases. The
patient subsequently received 3 cycles of chemotherapy (VAC
regimen: vincristine 2 mg plus doxorubicin 50 mg/m2 plus
cyclophosphamide 1000 mg/m2 every 21 days); however, the
patient experienced toxicity and further PD with an increase in
the dimensions and number of abdominal lymph node and
pelvic metastases, and cutaneous and subcutaneous nodules. At
this time, the patient also developed 1 asymptomatic brain
metastasis (largest diameter, 18 mm on October 2, 2017;
Figure 1). Due to the asymptomatic nature of the brain
metastasis, neurosurgery was not considered.
The patient began treatment with avelumab (10 mg/kg
intravenously every 2 weeks [Q2W]) on October 4, 2017; at
this time, the patient had an Eastern Cooperative Oncology
Group performance status (ECOG PS) of 1. Avelumab was
well tolerated, with no adverse events reported, and the patient
had reduced pain during the first 2-3 infusions; however, after a
total of 4 infusions, the treatment was stopped on November 14,
2017, because of further local (left thigh cutaneous lesion) and
systemic (brain metastasis) clinical and radiological progression.
The patient then received palliative care and died approximately
4 weeks later.
Patient Case 2
A 48-year-old woman from Italy with a family history of cancer
(biliary tract) was diagnosed with mMCC of the right inguinal
region with nodal (right lumboaortic, retrocrural, inguinal, and
common external iliac) and mammary gland metastases in
February 2017. The patient had moderate pain which was
controlled with paracetamol. No primary cutaneous lesion was
identified. Immunohistochemical analysis showed expression of
synaptophysin, cytokeratin (CK) 20, and high levels of Ki67
(70%). Between March and July 2017, the patient underwent 6
cycles of chemotherapy (cisplatin 30 mg/m2 plus etoposide 100
mg/m2 on days 1-3 every 21 days), with no relevant toxicity.
On August 18, 2017, a CT scan showed PD by RECIST 1.1 of
the nodal, lung, and bone regions and the appearance of an
asymptomatic meningeal metastasis close to the ethmoid region.
Due to the unusual location of the brain metastasis, the patient was
considered too high risk for neurosurgery. The patient was
enrolled in the avelumab global expanded access program on
August 30, 2017 and began treatment with avelumab (10 mg/kg
intravenously Q2W); at this time, the patient had an ECOG PS of
2. Avelumab was well tolerated, with a reduction in pain and no
adverse events reported; however, despite initial stable disease, the
patient experienced rapid PD (including the meningeal metastasis)
by RECIST 1.1 after 5 infusions. Avelumab treatment wasMay 2021 | Volume 11 | Article 672021
TABLE 1 | Summary of patient cases.
Patient case 2 Patient case 3 Patient case 4
Female Male
67 66
None High blood pressure,
depression, dyslipidemia




on external iliac nodes
Left axilla, neck, and supraclavicular
nodes
Retroclavicular, retropectoral,
and right axillary nodes
etoposide Carboplatin + etoposide, surgery Surgery, radiotherapy,
carboplatin + etoposide




2017 June 26, 2018 December 26, 2017
erapy 2L + SRS 2L with concurrent SRS
17 15
ase Complete response in 1 metastasis;
partial response in 1 metastasis*
Partial response†





Radiotherapy Nivolumab with concurrent
SRS
No No
Alive (November 2020) Alive (March 2021)
n 1.1; SRS, stereotactic radiosurgery.







































Age, years 70 48
Comorbidities Hyperuricemia, arterial hypertension, hypothyroidism
(treated with hormone replacement therapy)
None
Date of diagnosis of mMCC October 2016 February 2
Site of primary lesion Left thigh Unknown
Site of metastases at baseline Inguinal and paraaortic/iliac nodes Right lumb
and comm
Treatment before avelumab Cisplatin + etoposide Cisplatin +
Date brain metastases identified October 2, 2017 August 18
No. of brain metastases 1 1
Symptoms associated with brain
metastases
None None
ECOG PS at start of avelumab
treatment
1 2
Date of first avelumab dose October 4, 2017 August 30
Avelumab treatment 2L monotherapy 2L monoth
Approximate duration of avelumab
treatment at last follow-up, months
1 2
Best response to avelumab per RECIST
1.1
Progressive disease Stable dise
Toxicity associated with avelumab None None
Subsequent treatment Palliative care Radiothera
palliative ca
Avelumab treatment ongoing at last
follow-up
No No
Vital status at last follow-up (date) Died Died
2L, second line; mMCC, metastatic Merkel cell carcinoma; RECIST 1.1, Response Evaluation Criteria in Solid Tumors versio
*Patient achieved a partial response in 1 brain metastasis with avelumab, this metastasis then progressed (not confirmed by R
that metastasis.
†Patient achieved a complete response following subsequent nivolumab treatment.,
,
Fife et al. Case Report: Avelumab in Merkel Cell Carcinomasubsequently stopped on October 25, 2017. The patient then
underwent radiotherapy (39 Gy in 13 fractions) for the inguinal
metastasis and received subsequent chemotherapy (oral etoposide
50mg on days 1-14 every 28 days); however, by February 2018, the
patient had experienced further PD. The patient was then referred
to palliative care and died approximately 5 months later.
Patient Case 3
A 67-year-old British woman with a history of congenital jejunal
diverticular bleeding (treated with resection) was diagnosed with
mMCC in January 2017, after presenting with a large left axillary
mass and lymphoedema; no primary site was identified. The patient
did not have a family history of cancer. Immunohistochemical
analysis showed expression of synaptophysin, CD56, CK7,
and CK20 and no expression of thyroid transcription factor
1, calcitonin, or CDX-2. A PET-CT scan revealed high
fluorodeoxyglucose uptake in the left axilla (largest node,
39 mm), neck, and supraclavicular nodes. No primary skin lesion
was identified. The patient received 4 cycles of neoadjuvant
chemotherapy (carboplatin AUC 5 plus etoposide 120 mg/m2 on
days 1-3 every 28 days) and experienced a partial response by
RECIST 1.1 after 3 months (July 2017); however, the patient
subsequently experienced PD. In September 2017, the patient
underwent surgical dissections of the level I-V nodal regions in
the left side of the neck and a level I-III axillary node. Following
surgery, a PET-CT scan showed no fluorodeoxyglucose-avid
disease. The patient declined adjuvant radiotherapy due to the
risk of the left arm lymphoedema worsening.
In April 2018, a PET scan showed PD by RECIST 1.1 in the left
supraclavicular (30-mm node) and axilla regions, and a brain
magnetic resonance imaging (MRI) scan on May 9, 2018, showed
the presence of 2 asymptomatic brainmetastases in the right medial
temporal lobe adjacent to the optic chiasm (29 mm×25 mm) and
left occipital lobe (33 mm×31 mm; Figure 2A). Because of the
location of the temporal lobe metastasis, it was not possible to safely
undertake neurosurgery or stereotactic radiosurgery (SRS).Frontiers in Oncology | www.frontiersin.org 4On June 26, 2018, the patient began avelumab treatment (10
mg/kg intravenously Q2W); at this time, the patient had an
ECOG PS of 0. After 4 months of avelumab treatment, an MRI
scan on October 17, 2018, showed a complete response by
RECIST 1.1 of the occipital metastasis and a partial response
by RECIST 1.1 of the temporal lobe metastasis (reduced to
21 mm). On January 21, 2019, an MRI scan showed a
substantial decrease in the size of the temporal lobe metastasis
to 5 mm×3 mm; the left occipital lobe metastasis was cystic with
no enhancement (Table 2; Figure 2B).
On April 29, 2019, a brain MRI scan showed that the anterior
medial part of the right temporal lobe metastasis was larger
(maximum transverse dimension of 21 mm) and surrounded by
increased white matter edema (Figure 2C). There was no change
in the area of cystic encephalomalacia in the left occipital lobe
compared with January 2019. Given this observed progression in
the right temporal metastasis, avelumab treatment was paused
(from May 14 to June 23, 2019), and the patient began treatment
with fractionated SRS for this metastasis from May 31 to June 5,
2019 (25.5 Gy in 3 fractions).
On September 4, 2019, an MRI scan showed the right
temporal metastasis had reduced in size (maximum transverse
dimension of 8 mm; Figure 2D). In October 2019, clinical
evaluation showed enlargement of the left-sided neck mass,
and a PET scan showed a left-sided lower neck mass of
30 mm, fluorodeoxyglucose uptake in the small left upper
cervical node, and a new right upper cervical node. The patient
stopped avelumab treatment on November 25, 2019 and received
external beam radiotherapy to the bilateral neck region on
December 2, 2019, to improve localized control of the disease
progression (40 Gy in 15 fractions in 3 weeks [1 fraction per
day]). The patient then resumed avelumab treatment on January
13, 2020, for 2 cycles (last dose February 24, 2020). On January
25, 2020, an MRI scan showed a complete response by RECIST
1.1 of the brain metastases with no residual enhancement of the
right temporal lobe. On February 24, 2020, a CT scan showed aA B
FIGURE 1 | Development of an asymptomatic brain metastasis in patient case 1. Computed tomography brain scans of patient case 1 prior to initiating treatment
with avelumab (A) on August 16, 2017, and (B) on October 2, 2017.May 2021 | Volume 11 | Article 672021
Fife et al. Case Report: Avelumab in Merkel Cell Carcinomacomplete response by RECIST 1.1 in all metastases including in
the extracranial regions (i.e., the neck).
In March 2020, the patient had experienced 3 recent drop
attacks; cardiac investigations, including an implantable heart
monitor, detected sinus pauses of ≤28 seconds due to sinus node
disease. Cardiac MRI and echocardiogram were normal, as were
troponin, B-type natriuretic peptide, and creatine kinase
concentrations; the patient had no risk factors for cardiac
disease. Therefore, it was likely that this adverse event was
related to avelumab treatment. The patient received a dual
chamber pacemaker on April 7, 2020. MRI scans on June 16
(Figure 2E) and October 28, 2020 showed volume loss and no
enhancement of the brain metastases. At last follow-up, on
November 28, 2020, a body CT scan showed no recurrence ofFrontiers in Oncology | www.frontiersin.org 5metastases. The patient is delighted with the outcome of her
treatment and, having been off treatment for over a year,
continues to be able to maintain an active lifestyle.
Patient Case 4
A 66-year-old man from Algeria but treated in France with a
history of high blood pressure, depression, and dyslipidemia
presented with an asymptomatic, left parotid tumefaction in July
2015. He had no family history of cancer and no relevant prior
interventions. An exofacial left parotidectomy, including a biopsy of
areas II and IV, was performed in March 2016. This biopsy showed
a high-grade neuroendocrine carcinoma that was considered to be a
potential metastasis. A whole-body PET scan and a cervical,
thoracic, and abdominal CT scan had negative findings at theA B
C D
E
FIGURE 2 | Complete response of 2 asymptomatic brain metastases in patient case 3. Magnetic resonance imaging scans of patient case 3: (A) with 2 brain
metastases in the left occipital lobe and right temporal lobe prior to starting avelumab (May 9, 2018); (B) Complete response in occipital lobe and partial response in
temporal lobe metastases after 8 months of avelumab (January 21, 2019); (C) PD in temporal lobe metastasis after 10 months of avelumab (April 29, 2019; patient
began concurrent SRS on May 31, 2019); (D) substantial decrease in size of temporal lobe metastasis after SRS and 15 months of avelumab (September 4, 2019);
(E) Complete response in both metastases (June 16, 2020; avelumab treatment stopped on February 24, 2020).May 2021 | Volume 11 | Article 672021
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(60 Gy in 30 fractions) was performed on the surgical area from
May to July 2016. In June 2017, the patient presented with right
axillary adenopathy, and a whole-body PET scan and a cervical,
thoracic, and abdominal CT scan found substantial retroclavicular,
retropectoral, and right axillary node metastases. A biopsy of the
right axillary node was used to diagnose MCC.
From August 7 to October 18, 2017, the patient received 4
cycles of chemotherapy (carboplatin AUC 5 plus etoposide 100
mg/m2 on days 1-3 every 28 days). In November 2017, a CT scan
found node, muscle, and pararectal disease progression. In
December 2017, the patient presented with pain and
dysesthesia of the right arm due to right axillary adenopathy.
Second-line avelumab treatment (10 mg/kg Q2W) was started on
December 26, 2017, and was well tolerated (no adverse events
were reported and the pain and dysesthesia of the right arm
rapidly improved); at this time, the patient had an ECOG PS of 1.
On December 31, 2017, a brain MRI scan showed an
asymptomatic left cerebellar metastasis measuring <1 cm;
neurosurgery was not considered to be necessary, and the
patient received concurrent SRS (20 Gy in 1 fraction) of the
cerebellar metastasis and began palliative radiotherapy (30 Gy in
10 fractions) of the right axillary mass.
In March 2018, a CT scan showed an extracranial partial
response according to RECIST 1.1 (68% decrease), and an MRI
scan showed regression of the cerebellar metastasis. Avelumab
was discontinued in January 2019 after 25 cycles (13 months) of
treatment, due to the persistent partial response and the
difficulties for the patient to travel to receive avelumab.
Six months after avelumab treatment was stopped (July 2019),
a brain MRI scan showed recurrence of the cerebral metastasis,
justifying resumption of avelumab and 1 dose of SRS (16 Gy in 1
fraction). At this time, the patient was still experiencing an
extracranial partial response. After 2 months, the patient
switched from avelumab to nivolumab (anti–programmed
death 1 [PD-1]; 480 mg IV every month) to reduce the
patient’s travel burden. In July 2020, an MRI scan showed thatFrontiers in Oncology | www.frontiersin.org 6the patient remained in extracranial partial response and had
also achieved partial response of the brain metastases; however,
radionecrosis of the previously irradiated cerebral metastasis was
found, and the patient was subsequently treated with
corticosteroids 0.5 mg/kg with good resolution. At last follow-
up (March 2021), an MRI scan showed both intracranial and
extracranial complete response by RECIST 1.1.DISCUSSION
MCC is a rare tumor, but incidences have increased in recent
years with approximately 5000 new cases of MCC annually in the
US and Europe (11, 12). Patients with mMCC have a poor
prognosis, with historical 5-year OS rates of 35% and 14% for
nodal and distant disease, respectively (2). Current guidelines for
the treatment of mMCC recommend enrollment in a clinical trial
or systemic therapy with an anti–PD-1/PD-L1 antibody (4).
In 2017, avelumab became the first approved treatment for
mMCC based on the results of the JAVELIN Merkel 200 trial (8,
9). Initially, this approval was based on primary analysis results
from a cohort of patients with mMCC who received avelumab as
second-line or later treatment after disease progression with
chemotherapy (part A) (8) and preliminary data from a subset
of patients who received avelumab as first-line treatment, which
was initiated subsequently (part B) (9). After 3 years of follow-up
from part A of the trial (N=88), the objective response rate was
33.0% (95% CI, 23.3-43.8) and median duration of response was
40.5 months (95% CI, 18.0-not estimable). Median progression-
free survival and OS was 2.7 months (95% CI, 1.4-6.9) and 12.6
months (95% CI, 7.5-17.1), respectively (8, 13). After ≥15
months of follow-up in part B (N=116), the objective response
rate was 39.7% (95% CI, 30.7-49.2), and median duration of
response was 18.2 months (95% CI, 11.3-not estimable). Median
progression-free survival and OS was 4.1 months (95% CI, 1.4-
6.1) and 20.3 months (95% CI, 12.4-not estimable), respectively
(14). The JAVELIN Merkel 200 trial excluded patients withTABLE 2 | Timeline of treatments received and brain metastases size in patient case 3.
Date of MRI scan; treatment received Dimensions of brain metastases, mm
Right temporal lobe Left occipital lobe
May 9, 2018; prior to starting avelumab 29×25 33×31
June 26, 2018; started avelumab (10 mg/kg every 2 weeks)
July 23, 2018; 1 month of avelumab 27×19 32×35
October 17, 2018; 4 months of avelumab 21×9 NA (focal volume loss and no residual enhancement)
January 21, 2019; 8 months of avelumab 5×3 NA
April 29, 2019; 10 months of avelumab 21 (maximum transverse dimension) NA
May 14, 2019 to June 23, 2019; avelumab paused
May 31, 2019 to June 5, 2019; received SRS (25.5 Gy in 3 fractions over a week)
September 4, 2019; 14 months of avelumab* 8 (maximum transverse dimension) NA
January 25, 2020; 16 months of avelumab† NA (no residual enhancement) NA
June 16, 2020 NA (no intracranial mass or abnormal contrast enhancement) NA
October 28, 2020 NA (focal volume loss; no mass or enhancement) NA (focal volume loss; no mass or enhancement)MRI, magnetic resonance imaging; NA, not applicable; SRS, stereotactic radiosurgery.
*The patient stopped avelumab treatment on November 25, 2019, and received external beam radiotherapy to the bilateral neck region on December 2, 2019, to improve localized control
of the disease progression [40 Gy in 15 fractions in 3 weeks (1 fraction per day)].
†The patient resumed avelumab treatment on January 13, 2020, for 2 months (last avelumab dose February 24, 2020).May 2021 | Volume 11 | Article 672021
Fife et al. Case Report: Avelumab in Merkel Cell Carcinomaactive central nervous system metastases (8), and limited data are
available for the treatment of these patients.
In the cases reported here, patient age ranged from 48 to 70
years, 3 of the 4 patients were female, and 2 had comorbidities.
All patients had asymptomatic brain metastases and received
avelumab as second-line therapy following disease progression
with platinum-based chemotherapy. Avelumab treatment was
well tolerated in 3 patients; however, 1 patient (case 3) developed
sinus node disease that was likely related to avelumab treatment.
MCC is an aggressive cancer, and disease progression and
development of metastases can occur early (4). In the cases
reported here, slower tumor growth and the use of SRS appeared
to correlate with better response to subsequent avelumab
treatment. Two of the 4 patients experienced rapid
progression, with brain metastases identified approximately 6
months (patient 2) and 12 months (patient 1) after initial mMCC
diagnosis, and further disease progression with avelumab. In the
remaining 2 patients, progression appeared more gradual, with
brain metastases diagnosed approximately 16 months (patient 3)
and 22 months (patient 4) after initial diagnosis. With avelumab
treatment alone, patient 3 experienced a complete response in 1
brain metastasis and partial response in a second brain
metastasis; the second metastasis then progressed, but further
treatment with avelumab and SRS led to a complete response.
Patient 4 experienced a partial response with avelumab plus
concurrent SRS, and subsequently achieved a complete response
after switching to nivolumab treatment. Patient ECOG PS at the
time of starting avelumab treatment did not appear to be
associated with a better response.
Although no treatment options are recommended by guidelines
for patients with mMCC and brain metastases (4, 7), radiotherapy
is commonly used and has been associated with a survival benefit
(6). Furthermore, SRS with concurrent immunotherapy is
recommended by the European Society for Medical Oncology
for patients with melanoma and brain metastases (15). In a recent
study of 262 patients with melanoma and brain metastases,
radiotherapy combined with either immunotherapy or targeted
therapy was associated with a significantly reduced risk of death vs
systemic therapy (median OS 16.8 vs 6.9 months, respectively)
(16). In the cases reported here, SRS administered 11 months after
starting avelumab treatment (patient 3) or at the same time as
starting avelumab (patient 4) resulted in a complete response and a
partial response, respectively, and both patients were alive at last
follow-up. Neurosurgery has also been associated with prolonged
survival in patients with mMCC and brain metastases (6);
however, in the cases reported here, patients did not undergo
neurosurgery due to the asymptomatic nature of the metastases
and their locations being considered too high risk for resection.
Additionally, combining immunotherapy and SRS does not appear
to increase toxicity compared with SRS alone (17).
Furthermore, patients with nodal mMCC and no known
primary tumor location have been shown to have longer OS
compared with those with a known primary tumor site (2, 18).
This may be due to a more active immune response in some
patients that is able to eliminate the primary tumor (18). For the
2 patients with the longest OS in this series, cases 3 and 4, noFrontiers in Oncology | www.frontiersin.org 7primary tumor was identified. However, the dataset is small, and
immune markers were not analyzed; therefore, further research
is needed to investigate the potential mechanisms involved.
In summary, published data for patients with mMCC and
brain metastases are limited. We report the clinical experiences of
4 patients with mMCC and brain metastases treated in Europe
with avelumab after prior disease progression with chemotherapy.
In this small series, we show that avelumab can have intracerebral
and systemic activity and, when combined with radiotherapy
(both brain SRS and radiotherapy to other sites), can produce
lasting disease control. Although the optimal timing of SRS
administration warrants further investigation, the combination
of SRS and avelumab, along with more gradual disease
progression, appeared to be associated with improved survival.
Further research into potential predictors of response and
prolonged survival in this subset of patients is needed. Although
clinical trials in this small subset of patients are unlikely to be
feasible, prospective data on the use of SRS plus immunotherapy
in patients withmMCC and brainmetastases along with data from
trials investigating this combination in patients with other more
common tumor types will provide further insight into this
treatment strategy. Overall, our findings indicate that the use of
SRS with immunotherapy may be an effective treatment option for
patients with mMCC and brain metastases.DATA AVAILABILITY STATEMENT
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